risk of b-cell depleters long-term (ocrevus, rituximab, kesimpta, briumvi)
Published 1 year ago • 47K plays • Length 14:28Download video MP4
Download video MP3
Similar videos
-
16:26
blood tests for b-cell drugs (ocrevus, rituximab, kesimpta, briumvi)
-
19:30
ocrevus vs. rituximab (neurologist explains observational data)
-
0:16
how b cell killers treat ms
-
24:12
briumvi for multiple sclerosis explained by neurologist
-
11:56
colitis with ocrevus & rituximab
-
15:45
ocrevus vs. kesimpta for multiple sclerosis. comparison between the drugs, efficacy, side effects
-
6:00
2nd pml case with ocrevus reported by genentech
-
19:10
optimal dose of ocrevus for multiple sclerosis
-
![kesimpta (ofatumumab) for multiple sclerosis [asclepios i/ii trial results]](https://i.ytimg.com/vi/IIBBlvnPjS0/mqdefault.jpg)
14:03
kesimpta (ofatumumab) for multiple sclerosis [asclepios i/ii trial results]
-
![spms and ppms are the same (multiple sclerosis is one disease) [neurologist explains]](https://i.ytimg.com/vi/OboOmXJUdcs/mqdefault.jpg)
20:21
spms and ppms are the same (multiple sclerosis is one disease) [neurologist explains]
-
![ocrevus in primary progressive multiple sclerosis 6.5-year data [orotorio extension study]](https://i.ytimg.com/vi/YN0u0dYFYgQ/mqdefault.jpg)
14:19
ocrevus in primary progressive multiple sclerosis 6.5-year data [orotorio extension study]
-
16:36
if i had multiple sclerosis, what would i do?
-
44:14
multiple sclerosis overview (risk factors, diagnosis, treatment, diet)
-
13:37
do covid-19 vaccines work in people with ms taking ocrevus & gilenya? (data from the uk nhs)
-
7:17
multiple sclerosis | understanding the roles of b cells
-
3:09
why are b-cells such a valuable target in ms?
-
15:05
multiple sclerosis medication ranking 2023 based on network meta analysis
-
![is hsct for ms overrated? [neurologist reviews data vs. tysabri, ocrevus, and gilenya]](https://i.ytimg.com/vi/ybrfO7FkedU/mqdefault.jpg)
16:47
is hsct for ms overrated? [neurologist reviews data vs. tysabri, ocrevus, and gilenya]
-
21:01
tysabri pml risk & extended interval dosing